Friday, 22 Mar 2019

You are here

IL-18 Binding Protein Effective in Adult-Onset Still's Disease

Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).

The treatment of Still's disease has been revolutionized by the observation that this inflammasomopathy can be more effectively managed by inhibitors of IL-1 and IL-6.  But the same mechanisms driving excess IL-1 production and excessive caspase activity are mirrored by IL-18. 

They enrolled 21 adults with AOSD plus fever or or elevated C-reactive protein (CRP) levels and were treated with tadekinig alfa 80 mg (10 patients)  or 160 mg (13 patients) subcutaneously three times per week for 12 weeks.

By week 3, half of those treated with either 80 mg or 160 mg achieved the predefined response criteria.

They found 155 treatment-emerging AEs were recorded, most of which were mild, resolved and one-third were were considered related to the study drug.  There were 3 serious AEs occurred, one possibly related to treatment (toxic optic neuropathy).

These early results suggest and acceptable safety profile and good efficacy and warrants further controlled trial investigation in AOSD.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Multiple Delays in Referral of New RA Patients

A UK study of early onset arthritis or new rheumatoid arthritis patients shows multiple sources of delayed referral to the first rheumatology consultation.

Does Smoking Cessation Reduce RA Risk?

Individuals who quit smoking and maintained their nonsmoking status over a long duration of time had a decreased risk of developing seropositive rheumatoid arthritis (RA), an analysis of two large prospective cohorts found. 

Remission Unlikely in RA

Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.